$783 Million is the total value of Rhenman & Partners Asset Management AB's 94 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ANTH | Exit | Anthera Pharmaceuticals Inc Reg | $0 | – | -25,000 | -100.0% | -0.01% | – |
| OPHT | Exit | Ophthotech Corp | $0 | – | -23,920 | -100.0% | -0.01% | – |
| THLD | Exit | Threshold Pharmaceuticals | $0 | – | -201,537 | -100.0% | -0.01% | – |
| MRTX | Exit | Mirati Therapeutics Inc | $0 | – | -50,000 | -100.0% | -0.03% | – |
| TNDM | Exit | Tandem Diabetes Care Inc | $0 | – | -234,000 | -100.0% | -0.03% | – |
| OREXQ | Exit | Orexigen Therapeutics Inc | $0 | – | -120,000 | -100.0% | -0.05% | – |
| OCUL | Exit | Ocular Therapeutix Inc | $0 | – | -40,000 | -100.0% | -0.05% | – |
| CNCE | Exit | Concert Pharm Inc | $0 | – | -30,099 | -100.0% | -0.06% | – |
| CATB | Exit | Catabasis Pharmaceuticals Inc | $0 | – | -310,756 | -100.0% | -0.06% | – |
| FWP | Exit | Forward Pharma A/S spons ADS Level III repr 1 Share | $0 | – | -36,584 | -100.0% | -0.11% | – |
| ACAD | Exit | Acadia Pharmaceuticals Inc | $0 | – | -30,000 | -100.0% | -0.12% | – |
| SUPN | Exit | Supernus Pharmaceuticals Inc | $0 | – | -30,000 | -100.0% | -0.19% | – |
| HALO | Exit | Halozyme Therapeutics Inc | $0 | – | -120,000 | -100.0% | -0.22% | – |
| PODD | Exit | Insulet Corp | $0 | – | -35,000 | -100.0% | -0.26% | – |
| TTPH | Exit | Tetraphase Pharmaceuticals Inc | $0 | – | -300,000 | -100.0% | -0.31% | – |
| LH | Exit | Laboratory Corp of America Hgs | $0 | – | -20,000 | -100.0% | -0.44% | – |
| ENDP | Exit | Endo International Plc | $0 | – | -277,303 | -100.0% | -0.44% | – |
| HOLX | Exit | Hologic Inc | $0 | – | -70,000 | -100.0% | -0.46% | – |
| DVA | Exit | DaVita Inc | $0 | – | -55,000 | -100.0% | -0.51% | – |
| CAH | Exit | Cardinal Health Inc | $0 | – | -55,000 | -100.0% | -0.62% | – |
| TMO | Exit | Thermo Fisher Scientific Inc | $0 | – | -25,000 | -100.0% | -0.63% | – |
| NXTM | Exit | NxStage Medical Inc | $0 | – | -213,901 | -100.0% | -0.77% | – |
| AMGN | Exit | Amgen Inc | $0 | – | -35,000 | -100.0% | -0.86% | – |
| KITE | Exit | Kite Pharma Inc | $0 | – | -60,000 | -100.0% | -0.89% | – |
| ZBH | Exit | Zimmer Biomet Hgs Inc | $0 | – | -90,000 | -100.0% | -1.66% | – |
| Exit | NeuroDerm Ltd | $0 | – | -461,654 | -100.0% | -1.98% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-10-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.